Arcus Biosciences Inc（RCUS）财务数据RCUSArcus Biosciences Inc

Arcus Biosciences, Inc. (RCUS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaboration revenue, accounting for 61.0% of total sales, equivalent to $25.00M. Another important revenue stream is License and development services revenue. Understanding this composition is critical for investors evaluating how RCUS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Arcus Biosciences, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -234.15%, while the net margin is -221.95%. These profitability ratios, combined with a Return on Equity (ROE) of -90.82%, provide a clear picture of how effectively RCUS converts its operational activities into shareholder value.

In the context of the broader market, RCUS competes directly with industry leaders such as ABCL and IOVA. With a market capitalization of $3.90B, it holds a leading position in the sector. When comparing efficiency, RCUS's gross margin of 100.00% stands against ABCL's 100.00% and IOVA's 46.54%. Such benchmarking helps identify whether Arcus Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

The company's gross margin remains strong at 100%, indicating effective cost management in its operations. However, it has reported consistent net losses, with a net income of -91 million USD in Q2 2026. The forward P/E ratio is currently at 0, reflecting the company's transition phase as it develops its drug pipeline.